JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

11.54 -1.37

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.41

Max

11.85

Galvenie mērījumi

By Trading Economics

Ienākumi

-6.7M

-2M

Pārdošana

-1.4M

105M

P/E

Sektora vidējais

250.2

37.003

Peļņas marža

-1.882

Darbinieki

1,487

EBITDA

29M

30M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+31.03% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

397M

2B

Iepriekšējā atvēršanas cena

12.91

Iepriekšējā slēgšanas cena

11.54

Ziņu noskaņojums

By Acuity

50%

50%

156 / 373 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 3. nov. 21:44 UTC

Peļņas

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

2025. g. 3. nov. 23:44 UTC

Tirgus saruna

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

2025. g. 3. nov. 23:34 UTC

Tirgus saruna

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

2025. g. 3. nov. 23:28 UTC

Peļņas

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

2025. g. 3. nov. 23:24 UTC

Peļņas

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

2025. g. 3. nov. 23:14 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2025. g. 3. nov. 23:14 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

2025. g. 3. nov. 23:12 UTC

Peļņas

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

2025. g. 3. nov. 23:09 UTC

Peļņas

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

2025. g. 3. nov. 23:09 UTC

Peļņas

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

2025. g. 3. nov. 23:09 UTC

Peļņas

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

2025. g. 3. nov. 23:06 UTC

Tirgus saruna
Peļņas

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

2025. g. 3. nov. 22:36 UTC

Tirgus saruna
Peļņas

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

2025. g. 3. nov. 22:31 UTC

Peļņas

Franco-Nevada 3Q EPS $1.49 >FNV

2025. g. 3. nov. 22:31 UTC

Peļņas

Franco-Nevada 3Q Rev $487.7M >FNV

2025. g. 3. nov. 22:24 UTC

Tirgus saruna

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

2025. g. 3. nov. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Starbucks Agrees to Sell Stake in China Business -- WSJ

2025. g. 3. nov. 21:59 UTC

Tirgus saruna

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

2025. g. 3. nov. 21:54 UTC

Tirgus saruna
Peļņas

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

2025. g. 3. nov. 21:54 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 3. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 3. nov. 21:49 UTC

Peļņas

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

2025. g. 3. nov. 21:40 UTC

Peļņas

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

2025. g. 3. nov. 21:31 UTC

Tirgus saruna

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

2025. g. 3. nov. 21:19 UTC

Peļņas

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

2025. g. 3. nov. 21:11 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

2025. g. 3. nov. 21:11 UTC

Peļņas

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

2025. g. 3. nov. 21:07 UTC

Peļņas

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

2025. g. 3. nov. 21:05 UTC

Peļņas

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

2025. g. 3. nov. 21:05 UTC

Peļņas

Palantir Technologies 3Q Net $475.6M >PLTR

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

31.03% augšup

Prognoze 12 mēnešiem

Vidējais 15.33 USD  31.03%

Augstākais 16 USD

Zemākais 13 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

5

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

156 / 373 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat